 |
 |
||||||
[February 2010]
Amedica Signs JV Agreement with Orthopaedic Synergy
Amedica Corporation (Salt Lake City, UT, USA), a spinal and orthopaedic implant and instrument company focused on unique silicon nitride (SiN) ceramic technologies, has just announced an agreement with Orthopaedic Synergy Inc, a holding company for OMNIlife Science™ and Enztec, both global designers, manufacturers and distributors of leading edge reconstructive surgery implants and instrumentation.
Amedica is a full-line spinal implant company that owns and markets silicon nitride ceramic technologies that are now being utilised in spinal implant applications; however, the unique SiN materials have disruptive characteristics for hip and knee implant applications, as well. The material is fracture resistant; its bearing/articulating surfaces do not produce wear debris that is linked to osteolysis-related, re-operations. Additionally, the implants are BioActive™ with a hydrophilic surface and a conductive cancellous structure to enhance bone in-growth and attachment.
The Joint Venture Development Agreement will allow the development, regulatory approval and distribution of SiN articulating hip and knee implants in the USA and abroad. This agreement further secures both companies’ competitive positions in the largest segment of orthopaedic care.
Orthopaedic Synergy is a global reconstructive hip and knee implant and instrument concern that designs, manufactures and distributes its products. Its corporate headquarters is located in East Taunton, MA, USA and its design, development and manufacturing centre is based in Christchurch, New Zealand. OSI is known for leading-edge innovation, cost-effective, outcome-focused implant systems and deep orthopaedic executive management experience.
“Amedica’s SiN technology is ideally suited for the innovative modular hip and knee replacement products developed and marketed by our company, and we view this Joint Venture Development Agreement as a significant step forward in solving the issue of wear in reconstructive orthopaedic products,” said Nik Nikolaev, Chairman and CEO of Orthopaedic Synergy.
“Finding the appropriate material to use as a bearing surface in Total Joint Arthroplasty has been an elusive goal, especially for Total Hip Replacement. We have been investigating alternate materials for some time, and we are convinced that Amedica’s SiN technology is the answer. We are proud that they chose OSI to be their partner,” said George Cipolletti, President of OMNIlife Science.
“We are pleased that this agreement is now in place. SiN is a disruptive human implant material that has application in spine, reconstructive surgery and other orthopaedic implant indications. We are honored to be in this relationship with Orthopaedic Synergy – it is truly an alliance that, in time, can clearly enhance patient outcomes,” said Ben Shappley, CEO, President and Director of Amedica.
www.amedicacorp.com
ENDS